Determination of EPAC2 function using EPAC2 null Min6 sublines generated through CRISPR-Cas9 technology.

Area of Science:

• Endocrinology
• Cell Biology
• Molecular Biology

Background:

• Min6 cells are a key in vitro model for studying insulin secretion.
• Epac2 (Exchange protein directly activated by cyclic AMP 2) is implicated in pharmacologic stimuli-induced insulin secretion and is a potential sulfonylurea target.
• Previous studies focused only on EPAC2 isoform A, leaving other isoforms unexamined.

Purpose of the Study:

• To investigate the function of EPAC2 in Min6 cells by generating EPAC2 knockout sublines.
• To elucidate the role of all three EPAC2 isoforms in insulin secretion regulation.

Main Methods:

• CRISPR-Cas9 technology was used to generate EPAC2 knockout Min6 cell lines.
• Single-cell cloning, electroporation with guide RNA, Cas9, and GFP, followed by GFP sorting, was employed.
• Sequencing confirmed single nucleotide deletions causing frameshifts in EPAC2 exon 13.

Main Results:

• EPAC2 null clones exhibited increased basal insulin secretion and elevated intracellular insulin content.
• Glucose- and sulfonylurea-induced insulin secretion were impaired in EPAC2 deficient cells.
• Potassium chloride-induced insulin secretion and sulfonylurea binding remained unaffected; cAMP levels were unchanged.

Conclusions:

• EPAC2 plays a complex role in insulin secretion, beyond its function as a cAMP sensor.
• EPAC2 deficiency impacts previously unrecognized genes, suggesting involvement in multiple regulatory pathways.
• Complete EPAC2 knockout alters basal and stimulated insulin secretion in Min6 cells.